Nepanizil (Donepezil Hydrochloride)

Donepezil is used in the management of Alzheimer’s disease, a neurodegenerative disorder affecting cognition and function.

• Mild to moderate Alzheimer’s disease: improves cognitive function and daily living activities.
• Alzheimer’s disease-related behavioral symptoms: helps reduce agitation and confusion.
• Cognitive decline in early Alzheimer’s: provides symptomatic benefit in memory and attention.

• Donepezil Hydrochloride reversibly inhibits acetylcholinesterase, the enzyme responsible for breaking down acetylcholine in the synaptic cleft. By reducing enzymatic activity, it increases the concentration of acetylcholine in the brain, enhancing cholinergic neurotransmission and supporting cognitive processes that are diminished in Alzheimer’s disease.

Donepezil may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: increased bowel movements.
• Insomnia: difficulty falling or staying asleep.
• Muscle cramps: occasional skeletal muscle discomfort.
• Fatigue: feeling of tiredness or low energy.
• Loss of appetite: reduced desire to eat.

Serious or Rare Side Effects

• Bradycardia: significant slowing of heart rate.
• Syncope: fainting episodes.
• Severe vomiting: persistent, forceful emesis.
• Hepatic injury: abnormal liver function tests.
• Seizures: rare convulsive events.
• Allergic reactions: rash, swelling, or anaphylaxis.

When prescribing Donepezil, clinicians should consider several safety aspects.

• Dose adjustment: evaluate renal or hepatic impairment before initiating therapy.
• Cardiac monitoring: use caution in patients with conduction disorders or bradyarrhythmias.
• Discontinuation: avoid abrupt cessation as it may worsen cognition.
• Gastrointestinal risk: use carefully in patients with peptic ulcer disease.
• Pregnancy safety: unknown; prescribe only if benefits outweigh potential risks.
• Store at ambient temperature: keep in the original container, protect from moisture.

Donepezil can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations.
• Anticholinergic drugs: may diminish therapeutic effect.
• Other acetylcholinesterase inhibitors: risk of cholinergic excess.

Moderate Interactions (Monitor Closely)

• NSAIDs: may raise risk of gastrointestinal bleeding.
• Beta‑blockers: can exacerbate bradycardia.
• Antidepressants (e.g., SSRIs): monitor for additive serotonergic effects.